Melanoma antigens and their use in diagnostic and therapeutic me

Details Melanoma antigens and their use in diagnostic and therapeutic me Melanoma antigens and their use in diagnostic and therapeutic me

1998-01-16

1999-11-30

Burke, Julie

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

4242771, 4241741, 4243201, 530300, 435 911, 435371, 435344, 435 693, 514 15, 514 16, 536 231, A61K 3900, C07H 2104, C12N 1563

Patent

active

059945230

ABSTRACT:
The present invention provides a nucleic acid sequence encoding a melanoma antigen recognized by T lymphocytes, designated MART-1. This invention further relates to bioassays using the nucleic acid sequence, protein or antibodies of this invention to diagnose, assess or prognoses a mammal afflicted with melanoma or metastata melanoma. This invention also provides immunogenic peptides derived from the MART-1 melanoma antigen and a second melanoma antigen designated gp100. The proteins and peptides provided can serve as an immunogen or vaccine to prevent or treat melanoma.

REFERENCES:
patent: 5679511 (1997-10-01), Kwon
Lewin, Science vol. 237 p. 1570, 1987.
Reeck et al Cell vol. 50 p. 667, 1987.
Adema et al, Am. J. Pathol. vol. 143 p. 1579, Dec. 1993.
Kwon et al, PNAS vol. 88, p. 9221, Oct. 1991.

Affiliated with

Also associated with

Rating

Melanoma antigens and their use in diagnostic and therapeutic me does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Melanoma antigens and their use in diagnostic and therapeutic me, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanoma antigens and their use in diagnostic and therapeutic me will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1674353